General Description

This project follows the Columbia team’s identification of master regulator genes driving progression of gastroenteropancreatic neuroendocrine tumor to metastatic disease and of specific FDA approved drugs and investigational compounds that inhibit the activity of their associated proteins. These include compounds whose ability to abrogate master regulator has been validated in human tumors transplanted into immunocompromised mice. The new study aims to test the most specific and promising among these compounds to validate their ability to abrogate the aberrant activity of the identified master regulator proteins in tissue explants directly harvested from patients, which more closely represent the biology of the human tumor.